ViewsML Raises $4.9M to Commercialize AI-Powered Virtual Biomarker Staining Technology
核心洞察
ViewsML (搜索) completed an oversubscribed $4.9M seed funding round led by Wittington Ventures (搜索) to accelerate commercialization of its AI-driven virtual biomarker staining platform.
The company has developed the world's first virtual biomarker library that generates per-cell biomarker spatial insights from pathology images without laboratory staining.
The technology transforms traditional immunohistochemistry from a days-to-weeks laboratory process into software-based analysis completed in minutes.
ViewsML (搜索), a Vancouver-based company developing computational solutions for biomarker discovery, announced the completion of an oversubscribed $4.9M seed funding round led by Wittington Ventures (搜索). The funding round included new investors Continuum Health Ventures (搜索) and Mayo Clinic, alongside repeat investors RiSC Capital (搜索), Debiopharm (搜索), WUTIF, Defined, and e-Fund.
The investment reflects growing recognition of ViewsML (搜索)'s breakthrough technology in developing the world's first virtual biomarker library using artificial intelligence to generate per-cell biomarker spatial insights from pathology images without requiring laboratory staining.
Addressing Critical Bottlenecks in Biomarker Analysis
As demand for scalable, high-resolution biomarker data grows across drug development and diagnostics, traditional staining workflows have become a critical bottleneck. ViewsML (搜索)'s virtual biomarker staining represents a fundamental shift in how immunostaining is generated and analyzed, enabling an entirely new paradigm for assay development.
The company's scalable computational platform converts a traditionally lab-bound process into software via its first-of-its-kind virtual biomarker library. This technology delivers per-cell spatial biomarker insights from standard H&E slides, preserving scarce tissue samples while accelerating research, clinical trials, and patient care.
"Biomarkers are foundational to how we understand and treat disease, yet the way we measure them remains constrained by legacy approaches," said Zeeshan Ali, Partner at Wittington Ventures (搜索). "ViewsML (搜索) is redefining how biomarkers are measured and analyzed – unlocking a step-change in speed, scale, and accessibility across research and clinical settings."
Transforming Immunohistochemistry Workflows
The technology virtualizes immunohistochemistry (IHC), a diagnostic process that has remained largely unchanged for decades. ViewsML (搜索) enables scientists and clinicians to analyze biomarker staining in minutes rather than the days to weeks required by traditional laboratory workflows.
"We're building the computational layer for next-generation diagnostics, and are excited to partner with Wittington Ventures (搜索) and work with Mayo Clinic to accelerate that vision," said Kenneth To, CEO of ViewsML (搜索). "This capital will enable us to fast-track our efforts to revolutionize immunohistochemistry (IHC). By building the world's first virtual biomarker library, we're going to empower scientists and clinicians to analyze biomarker staining in minutes rather than the traditional days or weeks."
Strategic Partnerships and Commercial Applications
Through strategic collaborations with leading healthcare institutions, diagnostic companies, and biopharma organizations, ViewsML (搜索) is positioned to accelerate adoption across both research and clinical applications. The company is working with leading pharmaceutical companies, hospitals, and diagnostic labs to unlock the full biological value of existing pathology data.
The funding will be used to accelerate commercialization of ViewsML (搜索)'s AI-driven virtual biomarker staining platform, expand strategic partnerships, advance clinical validation of virtual biomarker panels, and grow the company's engineering, scientific, and commercial teams.
According to Ali, virtual staining has the potential to accelerate workflows, lower costs, and unlock new applications across translational research, diagnostics, clinical trials and emerging areas such as neurodegenerative disease (搜索), driving faster insights and improved patient outcomes.
ViewsML (搜索) will present its technology at the American Association for Cancer Research Annual Meeting 2026 from April 17-22, 2026, at the San Diego Convention Center in booth 1557, with several poster sessions alongside partners.